loader2
Partner With Us NRI

Dr Reddys Laboratories Ltd share Price Today

Company details

5,800.15
5,849.15
4,384.25
6,505.90
6M Return 3.35%
1Y Return 31.12%
Mkt Cap.(Cr) 96,746.93
Volume 22,645
Div Yield 0.69%
OI
-
OI Chg %
-
Volume 22,645

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
In line numbers boosted by gRevlimid, divestitures of brands…
About The Stock

    Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations.

    • Revenue breakup Q4FY23: US (41%), India (21%), Russia and CIS (12%), Europe (8%), RoW (6%), PSAI (12%)

    • It owns 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe

Q4FY23 Results

    Sales in line, margins beat. US, India, better than expected print.

    • Revenues grew 15.3% YoY to ₹ 6315 crore, mainly driven by growth in the US and India market followed by improvement on the Europe front

    • EBITDA margins grew 1,605 bps YoY to 24.3%

    • Adjusted PAT increased 192.6% YoY to ₹ 952.5 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Dr. Reddy's Laboratories announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Q4FY24 consolidated revenues at Rs 70.8 billion, YoY growth of 12%, and QoQ decline of 2%.
  • Gross Margin in Q4FY24 was at 58.6% (GG: 62.0%, PSAI: 28.6%), an increase of 140 basis points (bps) over the previous year and 7 bps sequentially. 
  • Selling, General & Administrative (SG&A) Expenses in Q4FY24 were Rs 20.5 billion, YoY increase of 14% and by 1 % QoQ
  • Research & Development (R&D) Expenses Q4FY24 were at Rs 6.9 billion. As % to Revenues - Q4FY24: 9.7% I Q3FY24: 7.7% I Q4FY23: 8.5%.
  • PBT: Q4FY24 at Rs 16.0 billion, YoY growth of 21 %, QoQ decline of 12%.
  • PAT: Q4FY24 at Rs 13.1 billion, YoY growth of 36%, QoQ decline of 5%
  • Diluted Earnings per Share (EPS): Q4FY24 is Rs 78.4
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA): Q4FY24 at Rs 18.7 billion, YoY growth of 15% and QoQ decline of 11%. EBITDA margin is 26.4%.

FY24 Financial Highlights:

  • FY24 consolidated revenues at Rs 279.2 billion, YoY growth of 14%.
  • Gross Margin in FY24 was at FY24 at 58.6% (GG: 62.9%, PSAI: 23.2%). Gross margin increased by 193 bps YoY. 
  • Selling, General & Administrative (SG&A) Expenses in FY24 were Rs 77.2 billion, YoY increase of 13%.
  • Research & Development (R&D) Expenses FY24 were at Rs 22.9 billion. As % to Revenues - FY24: 8.2% I FY23: 7.9%.
  • PBT: FY24 at Rs 71.9 billion, an increase of 19%. As % to Revenues - FY24: 25. 7% I FY23: 24.6%.
  • PAT: FY24 at Rs 55.7 billion, a growth of 24%. As % to Revenues - FY24: 19.9% I FY23: 18.3%.
  • Diluted Earnings per Share (EPS): FY24 is Rs 334.0
  • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA): FY24 at Rs 83.0 billion, a YoY growth of 14%. EBITDA margin is 29.7%.

Commenting on the results, Co-Chairman & MD, G V Prasad said: "Our growth and profitability in FY2024 has been driven by our performance in the US. We have also made significant progress on future growth drivers through licensing, collaboration and pipeline building. We will continue to strengthen our core businesses through superior execution as we invest and build the future growth drivers."

Result PDF

View Other Company Results

Dr Reddys Laboratories Ltd shares SWOT Analysis

Strengths (9)

  • Company with high TTM EPS Growth
  • Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
  • Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Weakness (3)

  • MFs decreased their shareholding last quarter
  • Declining profits every quarter for the past 2 quarters
  • Weak Momentum: Price below Short, Medium and Long Term Averages

Opportunity (3)

  • Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
  • Big Deal (Insider and SAST) buys last month greater than 1% of total shares
  • Big Deal (Insider and SAST) buys last week greater than 1% of total shares

Threats (2)

  • Red Flags: Firms linked to ongoing regulatory investigations/legal cases
  • RSI indicating price weakness

Resistance and support

R1 5,840.5
R2 5,869.3
R3 5,889.5
Pivot

5,820.30

S1 5,791.5
S2 5,771.3
S3 5,742.5
EMA SMA
5,999.0
6,071.2
6,013.3
5,782.7
6,052.4
6,132.5
6,070.9
5,839.5
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
BOFA SECURITIES EUROPE SA Block Purchase 2024-03-26 6184.85 260000 BSE
BOFA SECURITIES EUROPE SA Block Sell 2024-03-26 6184.85 260000 BSE
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Purchase 2024-01-18 5645.45 31907 BSE
Name Category Shares
KALLAM SATISH REDDY HUF PROMOTER 3.31%
GUNUPATI VENKATESWARA PRASAD HUF PROMOTER 1.52%
SAMRAJYAM REDDY KALLAM PROMOTER 0.67%
SATISH REDDY KALLAM PROMOTER 0.54%
APS Trust PROMOTER 20.59%

OUR RESEARCH VIEW

Trading recommendation

Call Date
15 May 2021
Entry Price 5,196.00
Target Price 5,570.00
Duration
Stop Loss -
Investment recommendation
In line numbers boosted by gRevlimid, divestitures of brands…
Call Date
11 May 2023
Entry Price 4,550.00
Target Price 5,520.00
Duration
12 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Dr Reddys Laboratories Ltd Stocks COMPARISON

Financials( in Cr) Dr Reddys Laboratories Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 5,799.55 1,531.40 1,399.05 1,051.40 3,910.75
% Change -1.28 0.26 -0.54 5.45 0.47
Mcap Cr 96,746.93 367,434.16 112,954.68 105,795.44 103,818.29
Revenue TTM Cr 24,669.70 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 4,507.30 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 17.39 39.15 26.62 28.83 75.36
1 Year Return 31.12 64.73 52.99 106.95 24.01
ROCE 25.99 16.79 14.76 16.25 19.30
ROE 21.21 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 23,413.00 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,096.27 -32,431.93
LAST 3M 103,643.75 -39,912.42
LAST 6M 170,661.45 50,171.66
LAST 12M 264,707.07 127,969.33
Dr. Reddy`s Laboratories Limited - Updates

May 18, 2024 l NSE Announcement

Dr. Reddy`s Laboratories Limited - Updates

May 17, 2024 l NSE Announcement

Dr. Reddy`s Laboratories Limited - Other General Purpose

May 16, 2024 l NSE Announcement

Date Action Type Ratio
Jul 11, 2023 Dividend 800
Jul 11, 2022 Dividend 600

Dr Reddys Laboratories Ltd Information

Stock PE (TTM)
17.39
Promoter Holding
26.65%
Book Value
1693.7479
ROCE
25.99%
ROE
21.21%
Description
  • Dr Reddy’s Laboratories Ltd. is an Indian multinational pharmaceutical company. It manufactures and markets a wide range of pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, and biologics. It was incorporated in 1984 with its headquarters in Hyderabad, Telangana. The company’s total income for the quarter ended June 2022 was Rs HYPERLINK "https://economictimes.indiatimes.com/dr-reddys-laboratories-ltd/stocks/companyid-13841.cms" 6,086.80 crore. On 5 August 2022, its market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/drreddyslaboratories/DRL" 69,190 crore.
    The company is listed on the Bombay Stock Exchange with the code 500124 and on the National Stock Exchange with the code DRREDDY. It is also listed on the MCX Stock Exchange.
    Dr Reddy’s Laboratories Ltd. has research and development centres and manufacturing facilities in 66 countries, with an employee strength of more than 24,000. For FY 2021-2022, the company’s profit after tax was Rs 2,182.50 crore, up 11.83% from FY 2020-2021. Its total assets for FY 2021-2022 stood at Rs 29,746.90 crore.
    The company’s shareholding pattern on 30 June 2022 indicated a promoter stake of 26.71%, foreign institutional investor stake of 25.87%, domestic institutional investor stake of 25.19%, and public stake of 21.96%. The promoters have decreased holdings from 26.72% to 26.71% in the June 2022 quarter, while the mutual fund holdings have increased from 14.12% to 14.21%.
    The company’s chairman is Mr K Satish Reddy. The co-chairman and managing director is Mr G V Prasad. The other board members include Mr Leo Puri, Ms Shikha Sharma, Dr Bruce L A Carter, Mr Allan Oberman, Mr Prasad R Menon, Ms Kalpana Morparia, and Mr Sridar Iyengar. The company’s auditors are S R Batliboi & Associates LLP.
    On 5 August 2022, Dr Reddy’s Laboratories Ltd.’s share price on BSE closed at Rs 4154. Its NSE share price closed at Rs 4,156.85. The company’s 52-week high share price was Rs 5,077, and the 52-week low was Rs 3,654.
    As of July 2022, the company’s mutual fund holdings included Franklin India Pension Plan, Aditya Birla SL Equity Hybrid ‘95 Fund, Franklin India Debt Hybrid Fund, and ICICI Prudential Regular Savings Fund with 1.04%, 0.79%, 0.62%, and 0.60% stake, respectively.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

8-2-337 Road No 3, Banjara Hills, Hyderabad, Telangana, 500034

Tel : 91-40-49002900
Email : shares:drreddys.com; mail:drreddys.com
Website : http://www.drreddys.com
Registrar

Bigshare Services Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 500124
NSE Code : DRREDDY
Book Closure Date (Month) : Jul
BSE Group : A
ISIN : INE089A01023

FAQ’s on Dr Reddys Laboratories Ltd Shares

You can buy Dr Reddys Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Dr Reddys Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 17, 2024 03:58 PM the closing price of Dr Reddys Laboratories Ltd was Rs.5,799.55.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 17, 2024 03:58 PM, the market cap of Dr Reddys Laboratories Ltd stood at Rs. 96,746.93.

The latest PE ratio of Dr Reddys Laboratories Ltd as of May 17, 2024 03:58 PM is 17.39

The latest PB ratio of Dr Reddys Laboratories Ltd as of May 17, 2024 03:58 PM is 0.29

The 52-week high of Dr Reddys Laboratories Ltd share price is Rs. 6,505.90 while the 52-week low is Rs. 4,384.25

According to analyst recommendations, Dr Reddys Laboratories Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app